15 Best Fast Growth Stocks To Buy Right Now

Page 7 of 15

9. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Number of Hedge Fund Holders: 57

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)  is a leading neuroscience-focused biopharmaceutical company. In the fourth quarter of 2024, GAAP net income and earnings per share were $103 million and $1, respectively, compared with $148 million and $1.44, respectively, for the fourth quarter of the prior year. In January, the firm announced an amended agreement with Takeda to develop and commercialize osavampator. The company will now have exclusive rights to develop and commercialize osavampator worldwide for all indications, except in Japan, where Takeda will retain exclusive rights. Both companies will share development costs in their respective regions and are eligible for royalty payments.

Page 7 of 15